Index - P/E - EPS (ttm) - Insider Own 53.70% Shs Outstand 31.85M Perf Week -1.69%
Market Cap 740.51M Forward P/E - EPS next Y - Insider Trans 98.80% Shs Float 14.75M Perf Month -
Income - PEG - EPS next Q - Inst Own - Short Float - Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio - Perf Half Y -
Book/sh -3.07 P/B - EPS next Y - ROA - Short Interest - Perf Year -
Cash/sh 1.74 P/C 13.40 EPS next 5Y - ROE - 52W Range 20.29 - 26.08 Perf YTD -1.69%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -10.85% Beta -
Dividend TTM - Quick Ratio 7.17 Sales past 5Y 0.00% Gross Margin - 52W Low 14.62% ATR (14) 2.78
Dividend Ex-Date - Current Ratio 7.17 EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility - -
Employees - Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom - Target Price -
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q - Payout - Rel Volume 0.77 Prev Close 21.23
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings - Avg Volume 469.70K Price 23.25
SMA20 6.62% SMA50 6.62% SMA200 6.62% Trades
Volume 233,287 Change 9.51%
Sep-18-24 03:19AM
Sep-16-24 04:05PM
Sep-12-24 07:11PM
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mathers Edward T Director Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:28 PM BASKETT FOREST 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:26 PM Behbahani Ali 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:24 PM Chang Carmen 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:23 PM Florence Anthony A. Jr. 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:21 PM Makhzoumi Mohamad 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:20 PM Walker Paul Edward 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:18 PM Yang Rick 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:17 PM SANDELL SCOTT D 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:14 PM ORBIMED ADVISORS LLC Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:13 PM New Enterprise Associates 17, 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:12 PM Frazier Life Sciences X, L.P. 10% Owner Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:11 PM Heron Patrick J Director Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:09 PM Aynechi Tiba Director Sep 16 '24 Buy 16.00 750,000 12,000,000 2,136,335 Sep 17 08:05 PM GORDON CARL L Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:05 PM
Index RUT P/E - EPS (ttm) -25.49 Insider Own 36.37% Shs Outstand 8.02M Perf Week -13.52%
Market Cap 333.22M Forward P/E - EPS next Y -9.79 Insider Trans 5.57% Shs Float 5.92M Perf Month -22.14%
Income -92.22M PEG - EPS next Q -2.55 Inst Own 62.88% Short Float 4.86% Perf Quarter 1.27%
Sales 0.00M P/S - EPS this Y 82.24% Inst Trans -28.19% Short Ratio 3.31 Perf Half Y -44.88%
Book/sh 21.34 P/B 1.68 EPS next Y -3.86% ROA -56.06% Short Interest 0.29M Perf Year 262.84%
Cash/sh 17.12 P/C 2.09 EPS next 5Y - ROE -75.75% 52W Range 4.57 - 97.91 Perf YTD -25.25%
Dividend Est. - P/FCF - EPS past 5Y -11.67% ROI -39.06% 52W High -63.41% Beta 3.85
Dividend TTM - Quick Ratio 13.28 Sales past 5Y -26.84% Gross Margin - 52W Low 683.17% ATR (14) 4.18
Dividend Ex-Date - Current Ratio 13.28 EPS Y/Y TTM 73.20% Oper. Margin 0.00% RSI (14) 37.89 Volatility 9.81% 10.12%
Employees 101 Debt/Eq 0.19 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 123.75
Option/Short No / Yes LT Debt/Eq 0.19 EPS Q/Q 83.89% Payout - Rel Volume 0.74 Prev Close 38.50
Sales Surprise - EPS Surprise -0.06% Sales Q/Q - Earnings Aug 13 AMC Avg Volume 86.90K Price 35.83
SMA20 -16.67% SMA50 -18.00% SMA200 -30.06% Trades
Volume 41,778 Change -6.94%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-14-24 Initiated William Blair
Outperform
$180
Mar-28-24 Reiterated H.C. Wainwright
Buy
$100 → $115
Feb-27-24 Initiated BMO Capital Markets
Outperform
$120
Dec-04-23 Initiated H.C. Wainwright
Buy
$100
Nov-29-23 Initiated RBC Capital Mkts
Outperform
$70
Nov-10-23 Initiated Piper Sandler
Overweight
$180
Feb-15-23 Downgrade Chardan Capital Markets
Buy → Neutral
Feb-13-23 Downgrade Cowen
Outperform → Market Perform
Sep-22-21 Downgrade Goldman
Buy → Neutral
$12 → $9
Jan-27-21 Upgrade JP Morgan
Neutral → Overweight
$56
Dec-22-20 Initiated B. Riley Securities
Buy
$79
Jul-14-20 Initiated Oppenheimer
Outperform
$36
May-18-20 Downgrade JP Morgan
Overweight → Neutral
$27
Oct-28-19 Initiated JP Morgan
Overweight
$25
Oct-28-19 Initiated Goldman
Buy
$30
Oct-28-19 Initiated Cowen
Outperform
Show Previous Ratings
Sep-16-24 08:00AM
Sep-10-24 08:00AM
Aug-28-24 08:00AM
Aug-27-24 08:00AM
Aug-13-24 04:01PM
08:00AM
Loading…
Jul-01-24 08:00AM
Jun-25-24 12:53PM
May-30-24 04:01PM
May-20-24 02:30PM
May-14-24 10:55PM
04:01PM
Apr-18-24 08:30AM
Apr-01-24 04:01PM
Mar-26-24 04:01PM
Feb-27-24 09:55AM
08:00AM
Loading…
08:00AM
Feb-09-24 09:55AM
Jan-18-24 08:00AM
Jan-04-24 08:00AM
Dec-07-23 08:00AM
Nov-28-23 08:00AM
Nov-03-23 03:31PM
12:19PM
Aug-10-23 04:01PM
Jul-17-23 11:59AM
Jul-14-23 11:22AM
06:30AM
May-12-23 04:01PM
Mar-10-23 07:30AM
Feb-27-23 07:30AM
01:55PM
Loading…
Feb-13-23 01:55PM
(American City Business Journals) -80.54%
11:17AM
08:05AM
Dec-19-22 07:30AM
Dec-15-22 07:30AM
Nov-17-22 07:30AM
Nov-08-22 04:05PM
Oct-12-22 07:30AM
Aug-30-22 07:30AM
Aug-09-22 04:05PM
(Business Wire) -11.11%
+9.00%
Jun-24-22 09:03AM
May-25-22 12:00PM
May-18-22 07:30AM
May-04-22 04:30PM
Apr-22-22 07:30AM
Apr-08-22 05:00PM
Mar-15-22 07:30AM
Mar-10-22 06:35PM
Feb-28-22 07:30AM
Jan-14-22 05:43AM
Jan-04-22 07:30AM
Dec-28-21 02:38AM
Dec-09-21 01:18PM
07:30AM
Nov-30-21 05:53AM
Nov-15-21 12:25PM
07:30AM
Nov-09-21 07:30AM
Nov-08-21 03:00PM
Oct-27-21 07:30AM
Oct-21-21 07:30AM
Oct-01-21 08:23AM
Sep-22-21 11:18AM
07:30AM
Sep-08-21 07:30AM
Aug-30-21 05:10PM
Aug-12-21 04:06PM
08:45AM
07:30AM
Aug-04-21 03:00PM
Aug-02-21 03:05PM
02:30PM
12:30PM
12:30PM
11:00AM
10:00AM
09:16AM
09:09AM
05:50AM
03:27AM
Aug-01-21 10:38AM
06:36AM
Jul-30-21 08:49PM
07:19PM
07:10PM
05:15PM
02:57PM
01:30PM
12:40PM
11:30AM
11:30AM
11:00AM
10:00AM
10:00AM
09:30AM
09:00AM
05:18AM
Jul-29-21 08:47PM
05:29PM
04:02PM
Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Colletti Steve Former Officer Aug 30 '24 Proposed Sale 49.24 10,303 507,326 Aug 30 05:28 PM New Enterprise Associates 17, 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM BASKETT FOREST 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Florence Anthony A. Jr. 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Walker Paul Edward 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Chang Carmen 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Mathers Edward T 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Yang Rick 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Makhzoumi Mohamad 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM SANDELL SCOTT D 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Atlas Venture Opportunity Fund 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 195,074 Apr 23 05:23 PM Lucchino David L. Director Nov 22 '23 Sale 37.69 1,156 43,573 22,150 Nov 27 08:48 PM Lucchino David L. Director Nov 10 '23 Sale 41.97 968 40,632 23,306 Nov 22 04:05 PM
Index RUT P/E - EPS (ttm) -0.42 Insider Own 44.31% Shs Outstand 138.14M Perf Week 8.12%
Market Cap 747.45M Forward P/E - EPS next Y -0.43 Insider Trans 0.00% Shs Float 91.67M Perf Month 1.36%
Income -75.29M PEG - EPS next Q -0.11 Inst Own 51.05% Short Float 10.27% Perf Quarter 17.04%
Sales 0.00M P/S - EPS this Y -35.06% Inst Trans 2.44% Short Ratio 5.34 Perf Half Y -7.14%
Book/sh 0.74 P/B 6.17 EPS next Y 3.85% ROA -58.02% Short Interest 9.41M Perf Year 20.45%
Cash/sh 0.74 P/C 6.15 EPS next 5Y - ROE -79.48% 52W Range 3.12 - 5.70 Perf YTD -3.38%
Dividend Est. - P/FCF - EPS past 5Y 29.09% ROI -58.72% 52W High -20.33% Beta 0.96
Dividend TTM - Quick Ratio 11.29 Sales past 5Y -20.00% Gross Margin - 52W Low 45.78% ATR (14) 0.22
Dividend Ex-Date - Current Ratio 11.29 EPS Y/Y TTM -51.68% Oper. Margin 0.00% RSI (14) 56.17 Volatility 5.14% 4.97%
Employees 37 Debt/Eq 0.26 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 10.79
Option/Short Yes / Yes LT Debt/Eq 0.26 EPS Q/Q -62.62% Payout - Rel Volume 0.63 Prev Close 4.64
Sales Surprise - EPS Surprise -15.05% Sales Q/Q - Earnings Aug 12 AMC Avg Volume 1.76M Price 4.54
SMA20 4.44% SMA50 3.05% SMA200 -0.35% Trades
Volume 721,399 Change -2.13%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated JMP Securities
Mkt Outperform
$8
Nov-07-23 Initiated Guggenheim
Buy
$7
May-16-23 Upgrade Jefferies
Hold → Buy
$2 → $4
Mar-31-23 Downgrade Jefferies
Buy → Hold
$2
Mar-16-21 Initiated Piper Sandler
Overweight
$7
Mar-15-21 Initiated Oppenheimer
Outperform
$4
Jun-13-19 Reiterated H.C. Wainwright
Buy
$22 → $6
Jun-13-19 Downgrade Ladenburg Thalmann
Buy → Neutral
$21 → $3
Jun-13-19 Downgrade JMP Securities
Mkt Outperform → Mkt Perform
Aug-13-18 Resumed ROTH Capital
Neutral
$12
Jan-03-18 Initiated Ladenburg Thalmann
Buy
$35
Sep-27-17 Resumed ROTH Capital
Buy
$40
Sep-22-17 Initiated Jefferies
Buy
$20
Sep-11-17 Initiated JMP Securities
Mkt Outperform
$20
Show Previous Ratings
Sep-08-24 06:45AM
Sep-06-24 04:05PM
Sep-03-24 04:05PM
Sep-01-24 10:26PM
Aug-29-24 08:41PM
04:05PM
Loading…
Aug-16-24 04:05PM
Aug-15-24 08:05AM
Aug-12-24 04:05PM
Jun-29-24 08:35PM
06:30PM
Jun-28-24 08:50AM
Jun-26-24 07:41AM
06:30AM
Jun-25-24 08:05PM
Jun-19-24 09:00AM
06:00AM
Loading…
Jun-11-24 06:00AM
May-29-24 08:05AM
May-21-24 08:20AM
May-19-24 12:15PM
May-16-24 04:05PM
May-09-24 10:55PM
04:05PM
May-07-24 04:05PM
(Business Wire) +6.26%
-5.13%
Apr-08-24 08:05AM
Mar-22-24 04:05PM
Mar-07-24 10:54PM
04:05PM
Mar-06-24 04:05PM
Feb-02-24 08:05AM
Jan-31-24 08:05AM
03:01PM
Loading…
Dec-30-23 03:01PM
Dec-21-23 08:05AM
Dec-20-23 08:05AM
Dec-15-23 04:05PM
Nov-21-23 08:05AM
Nov-09-23 04:05PM
Nov-08-23 04:05PM
Oct-06-23 04:05PM
Sep-27-23 07:29PM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-05-23 04:05PM
Aug-10-23 04:05PM
Aug-04-23 04:05PM
Jul-13-23 07:00AM
Jun-26-23 04:05PM
08:05AM
Jun-02-23 08:05AM
May-28-23 08:26AM
May-16-23 12:32PM
May-15-23 08:05AM
May-05-23 04:05PM
Apr-03-23 07:33AM
Mar-31-23 04:05PM
Mar-30-23 04:05PM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 04:05PM
07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 04:05PM
06:43AM
Feb-27-23 06:50AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
06:24AM
Feb-14-23 08:05AM
06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 03:47PM
07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 08:05AM
06:55AM
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pauls Matthew CHIEF EXECUTIVE OFFICER Dec 28 '23 Sale 4.71 84,000 395,900 1,302,674 Dec 29 04:35 PM Lowrance David L CHIEF FINANCIAL OFFICER Dec 28 '23 Sale 4.71 10,000 47,131 342,355 Dec 29 04:34 PM Elam Nevan C Director Dec 28 '23 Option Exercise 1.30 53,758 69,722 116,343 Dec 29 04:33 PM Elam Nevan C Director Dec 28 '23 Sale 4.71 93,843 442,291 22,500 Dec 29 04:33 PM Hawkins Richard J Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 12,741 Dec 12 06:09 PM Elam Nevan C Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 40,085 Dec 12 06:08 PM
Index RUT P/E - EPS (ttm) -0.63 Insider Own 16.79% Shs Outstand 155.32M Perf Week 3.73%
Market Cap 1.29B Forward P/E 29.31 EPS next Y 0.28 Insider Trans -1.78% Shs Float 130.57M Perf Month -1.97%
Income -96.68M PEG - EPS next Q 0.02 Inst Own 72.46% Short Float 6.86% Perf Quarter 24.32%
Sales 673.83M P/S 1.91 EPS this Y 1967.01% Inst Trans -0.67% Short Ratio 3.55 Perf Half Y -43.02%
Book/sh 3.73 P/B 2.20 EPS next Y 35.44% ROA -10.61% Short Interest 8.95M Perf Year -55.01%
Cash/sh 4.53 P/C 1.81 EPS next 5Y - ROE -15.96% 52W Range 6.35 - 21.26 Perf YTD -57.64%
Dividend Est. - P/FCF 20.58 EPS past 5Y -21.68% ROI -16.52% 52W High -61.40% Beta 1.43
Dividend TTM - Quick Ratio 2.52 Sales past 5Y 37.04% Gross Margin 52.28% 52W Low 29.22% ATR (14) 0.41
Dividend Ex-Date - Current Ratio 2.52 EPS Y/Y TTM 38.82% Oper. Margin -18.84% RSI (14) 54.34 Volatility 4.36% 4.10%
Employees 1295 Debt/Eq 0.00 Sales Y/Y TTM 16.19% Profit Margin -14.35% Recom 1.53 Target Price 15.92
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q 30.40% Payout - Rel Volume 0.56 Prev Close 8.40
Sales Surprise 3.42% EPS Surprise 710.81% Sales Q/Q 10.82% Earnings Jul 25 AMC Avg Volume 2.52M Price 8.21
SMA20 3.77% SMA50 2.57% SMA200 -33.55% Trades
Volume 920,167 Change -2.32%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-19-24 Initiated BofA Securities
Buy
$11
Apr-30-24 Reiterated Telsey Advisory Group
Outperform
$25 → $18
Jan-19-24 Downgrade Goldman
Neutral → Sell
$18 → $14
Oct-12-23 Initiated BMO Capital Markets
Outperform
$24
Jul-28-23 Upgrade Cantor Fitzgerald
Neutral → Overweight
$13 → $17
Feb-27-23 Downgrade Truist
Buy → Hold
$17.50 → $12
Feb-10-23 Downgrade Cantor Fitzgerald
Overweight → Neutral
$17 → $16
Jul-29-22 Downgrade UBS
Buy → Neutral
Jul-28-22 Downgrade Stifel
Buy → Hold
$26 → $14
Jul-28-22 Downgrade Raymond James
Outperform → Mkt Perform
Jul-28-22 Downgrade Goldman
Buy → Neutral
$23 → $14
Mar-30-22 Initiated Cantor Fitzgerald
Overweight
$30
Jan-07-22 Upgrade Goldman
Neutral → Buy
$32
Aug-04-21 Upgrade Raymond James
Mkt Perform → Outperform
$45
Jun-29-21 Resumed DA Davidson
Buy
$55 → $52
Jun-11-21 Resumed RBC Capital Mkts
Outperform
$50
Apr-26-21 Initiated William Blair
Outperform
Apr-26-21 Initiated UBS
Buy
$54
Apr-26-21 Initiated Truist
Buy
$54
Apr-26-21 Initiated Telsey Advisory Group
Outperform
Show Previous Ratings
Sep-19-24 11:38AM
(Yahoo Finance Video) +9.80%
Sep-18-24 03:00PM
Sep-17-24 09:10AM
Aug-29-24 03:51AM
Aug-26-24 04:30AM
07:00AM
Loading…
Aug-14-24 07:00AM
Aug-08-24 11:42AM
Aug-03-24 08:34AM
Aug-01-24 10:00AM
Jul-29-24 06:09PM
11:10AM
Jul-26-24 04:16PM
02:23PM
01:55PM
12:30PM
11:01AM
Loading…
11:01AM
10:35AM
10:29AM
07:36AM
Jul-25-24 07:00PM
05:35PM
04:56PM
04:28PM
(Associated Press Finance)
04:10PM
Jul-24-24 03:08AM
Jul-19-24 02:07PM
Jul-17-24 02:05PM
01:44PM
06:58AM
Jul-15-24 04:13AM
04:06AM
Loading…
Jul-12-24 04:06AM
Jul-11-24 04:10PM
Jul-08-24 03:48AM
Jul-03-24 02:00PM
Jun-29-24 04:29AM
04:27AM
Jun-24-24 12:44PM
Jun-23-24 06:59PM
Jun-12-24 02:43PM
12:30PM
Jun-10-24 02:01PM
10:45AM
06:12AM
Jun-07-24 09:41PM
09:40PM
May-31-24 09:17PM
09:15PM
May-28-24 04:10AM
May-26-24 03:42AM
03:33AM
May-20-24 11:16AM
08:30AM
May-18-24 02:37AM
May-13-24 04:15PM
12:16PM
May-12-24 05:27PM
10:29AM
May-11-24 02:44AM
May-09-24 06:38PM
01:31PM
May-08-24 06:19PM
06:36AM
May-06-24 07:01PM
05:05PM
04:50PM
12:39PM
06:00AM
May-04-24 04:18PM
04:18PM
May-01-24 12:51PM
Apr-30-24 04:21PM
03:49PM
(The Wall Street Journal)
02:24PM
01:29PM
12:16PM
11:36AM
09:21AM
09:20AM
09:20AM
09:19AM
08:50AM
08:33AM
07:40AM
07:31AM
06:48AM
06:36AM
03:09AM
Apr-29-24 08:54PM
06:30PM
05:27PM
05:12PM
04:45PM
(Associated Press Finance)
04:39PM
04:10PM
Apr-28-24 10:23PM
03:01AM
Apr-27-24 09:37AM
Apr-26-24 08:02PM
04:40PM
Apr-22-24 05:32PM
Coursera, Inc. is an online learning platform, which engages in the provision of online courses and degrees from universities and companies. It offers arts, chemistry, engineering, food, and nutrition, health, humanities, law, medicine, and music. The firm operates through the following segments: Consumer, Enterprise, and Degrees. The Consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers. The Enterprise segment consists of serving businesses, governmental organizations, and academic institutions by providing an intuitive online platform with access to job-relevant educational content enabling them to train, upskill, and reskill their employees, citizens, and students, faculty, and staff, respectively. The Degrees segment consists of partnering with universities to deliver fully online bachelor's and master's degrees. Coursera was founded by Daphne Koller and Andrew Y. Ng in 2011 and is headquartered in Mountain View, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ng Andrew Y. Director Sep 18 '24 Proposed Sale 8.01 6,221 49,830 Sep 18 04:17 PM Ng Andrew Y. Director Aug 21 '24 Option Exercise 1.68 100,000 168,000 7,303,892 Aug 23 06:22 PM Ng Andrew Y. Director Aug 21 '24 Sale 8.40 25,000 210,067 7,203,892 Aug 23 06:22 PM Clark Amanda Director Aug 15 '24 Sale 8.23 1,562 12,857 74,704 Aug 19 08:03 PM Cardenas Alan B SVP, General Counsel Aug 19 '24 Sale 8.27 6,285 52,007 207,434 Aug 19 07:50 PM SHRAVAN GOLI Officer Aug 19 '24 Proposed Sale 8.25 35,449 292,454 Aug 19 04:25 PM LEAH BELSKY Officer Aug 19 '24 Proposed Sale 8.25 38,108 314,391 Aug 19 04:25 PM RICHARD JACQUET Officer Aug 19 '24 Proposed Sale 8.25 16,453 135,737 Aug 19 04:25 PM ALAN B CARDENAS Officer Aug 19 '24 Proposed Sale 8.25 6,285 51,851 Aug 19 04:24 PM AMANDA CLARK Director Aug 15 '24 Proposed Sale 7.77 1,562 12,137 Aug 15 04:30 PM Ng Andrew Y. Director Jul 17 '24 Option Exercise 1.68 100,000 168,000 7,228,892 Jul 19 04:41 PM Ng Andrew Y. Director Jun 12 '24 Option Exercise 1.68 96,019 161,312 7,128,892 Jun 14 05:01 PM Clark Amanda Director May 24 '24 Sale 7.72 8,093 62,456 76,266 May 24 06:23 PM SIMMONS SABRINA Director May 24 '24 Sale 7.72 8,093 62,447 37,785 May 24 06:18 PM Ng Andrew Y. Director May 21 '24 Option Exercise 1.68 3,981 6,688 7,037,055 May 23 05:31 PM Ng Andrew Y. Director May 22 '24 Sale 8.10 18,870 152,907 7,032,873 May 23 05:31 PM Ng Andrew Y. Director May 21 '24 Sale 8.56 3,981 34,079 7,033,074 May 23 05:31 PM Clark Amanda Director May 15 '24 Sale 8.92 1,562 13,933 65,690 May 17 06:03 PM Cardenas Alan B SVP, General Counsel May 17 '24 Sale 8.56 6,283 53,811 220,589 May 17 05:56 PM JACQUET RICHARD J SVP, Chief People Officer May 17 '24 Sale 8.56 16,453 140,880 198,954 May 17 05:47 PM JACQUET RICHARD J SVP, Chief People Officer May 08 '24 Sale 9.40 16,273 152,903 249,456 May 10 06:10 PM Maggioncalda Jeffrey Nacey President & CEO May 02 '24 Sale 9.60 50,000 480,010 2,127,496 May 06 04:46 PM Maggioncalda Jeffrey Nacey President & CEO Apr 18 '24 Sale 11.91 50,000 595,505 2,177,496 Apr 22 05:26 PM Meyers Michele M VP, Accounting, and CAO Apr 18 '24 Sale 12.00 2,880 34,560 240,159 Apr 22 05:23 PM Ng Andrew Y. Director Apr 16 '24 Option Exercise 1.68 50,000 84,000 7,108,074 Apr 18 06:04 PM Ng Andrew Y. Director Apr 16 '24 Sale 12.09 50,000 604,490 7,058,074 Apr 18 06:04 PM Ng Andrew Y. Director Apr 17 '24 Sale 11.95 25,000 298,840 7,033,074 Apr 18 06:04 PM Maggioncalda Jeffrey Nacey President & CEO Apr 11 '24 Sale 13.14 50,000 656,760 2,227,496 Apr 15 05:17 PM Maggioncalda Jeffrey Nacey President & CEO Mar 28 '24 Sale 14.06 50,000 703,205 2,277,496 Apr 01 05:12 PM Belsky Leah F. Chief Revenue Officer Mar 21 '24 Option Exercise 7.91 10,000 79,100 913,282 Mar 25 06:18 PM Belsky Leah F. Chief Revenue Officer Mar 21 '24 Sale 14.46 10,000 144,589 903,282 Mar 25 06:18 PM Ng Andrew Y. Director Mar 19 '24 Option Exercise 1.68 50,000 84,000 7,133,074 Mar 21 06:02 PM Ng Andrew Y. Director Mar 19 '24 Sale 14.18 50,000 709,200 7,083,074 Mar 21 06:02 PM Ng Andrew Y. Director Mar 20 '24 Sale 14.44 25,000 361,070 7,058,074 Mar 21 06:02 PM Meyers Michele M VP, Accounting, and CAO Mar 20 '24 Sale 14.43 2,880 41,545 243,039 Mar 20 08:00 PM Maggioncalda Jeffrey Nacey President & CEO Mar 14 '24 Sale 14.45 50,000 722,555 2,327,496 Mar 18 04:57 PM Maggioncalda Jeffrey Nacey President & CEO Feb 29 '24 Sale 15.94 50,000 797,180 2,377,496 Mar 04 05:33 PM Belsky Leah F. Chief Revenue Officer Feb 27 '24 Sale 16.29 42,756 696,589 837,338 Feb 29 05:02 PM Ng Andrew Y. Director Feb 20 '24 Option Exercise 1.68 50,000 84,000 7,158,074 Feb 22 05:19 PM Ng Andrew Y. Director Feb 20 '24 Sale 16.49 50,000 824,340 7,108,074 Feb 22 05:19 PM Ng Andrew Y. Director Feb 21 '24 Sale 16.22 25,000 405,442 7,083,074 Feb 22 05:19 PM Goli Shravan Chief Operating Officer Feb 20 '24 Sale 16.48 35,450 584,294 737,641 Feb 20 07:11 PM Cardenas Alan B SVP, General Counsel Feb 20 '24 Sale 16.54 5,864 97,010 167,798 Feb 20 07:08 PM Clark Amanda Director Feb 15 '24 Sale 16.85 1,562 26,317 67,252 Feb 20 07:00 PM Meyers Michele M VP, Accounting, and CAO Feb 15 '24 Sale 16.86 2,540 42,818 206,059 Feb 20 06:55 PM Maggioncalda Jeffrey Nacey President & CEO Feb 15 '24 Option Exercise 2.56 22,595 57,843 2,574,525 Feb 20 06:51 PM Maggioncalda Jeffrey Nacey President & CEO Feb 15 '24 Sale 16.85 50,000 842,330 2,524,525 Feb 20 06:51 PM HAHN KENNETH R SVP, Chief Financial Officer Feb 14 '24 Option Exercise 6.06 5,000 30,300 557,715 Feb 16 05:34 PM HAHN KENNETH R SVP, Chief Financial Officer Feb 14 '24 Sale 17.01 25,000 425,245 532,715 Feb 16 05:34 PM Maggioncalda Jeffrey Nacey President & CEO Feb 01 '24 Option Exercise 2.56 50,000 128,000 2,601,930 Feb 05 05:34 PM Maggioncalda Jeffrey Nacey President & CEO Feb 02 '24 Option Exercise 2.56 25,000 64,000 2,576,930 Feb 05 05:34 PM Maggioncalda Jeffrey Nacey President & CEO Feb 01 '24 Sale 19.20 50,000 959,935 2,551,930 Feb 05 05:34 PM Maggioncalda Jeffrey Nacey President & CEO Feb 02 '24 Sale 20.14 25,000 503,542 2,551,930 Feb 05 05:34 PM Maggioncalda Jeffrey Nacey President & CEO Jan 29 '24 Option Exercise 2.56 50,000 128,000 2,601,930 Jan 31 05:39 PM Maggioncalda Jeffrey Nacey President & CEO Jan 29 '24 Sale 20.06 50,000 1,002,895 2,551,930 Jan 31 05:39 PM HAHN KENNETH R SVP, Chief Financial Officer Jan 23 '24 Option Exercise 6.06 5,000 30,300 557,715 Jan 25 05:35 PM HAHN KENNETH R SVP, Chief Financial Officer Jan 23 '24 Sale 18.39 5,000 91,945 552,715 Jan 25 05:35 PM Goli Shravan Chief Operating Officer Jan 22 '24 Option Exercise 2.23 8,750 19,512 818,273 Jan 24 05:31 PM Goli Shravan Chief Operating Officer Jan 22 '24 Sale 17.96 8,750 157,179 809,523 Jan 24 05:31 PM Maggioncalda Jeffrey Nacey President & CEO Jan 18 '24 Option Exercise 2.56 50,000 128,000 2,601,930 Jan 22 05:34 PM Maggioncalda Jeffrey Nacey President & CEO Jan 18 '24 Sale 19.43 50,000 971,390 2,551,930 Jan 22 05:34 PM Ng Andrew Y. Director Jan 16 '24 Option Exercise 1.68 50,000 84,000 7,183,074 Jan 18 06:27 PM Ng Andrew Y. Director Jan 16 '24 Sale 19.59 50,000 979,550 7,133,074 Jan 18 06:27 PM Ng Andrew Y. Director Jan 17 '24 Sale 19.29 25,000 482,370 7,108,074 Jan 18 06:27 PM Maggioncalda Jeffrey Nacey President & CEO Jan 04 '24 Option Exercise 2.56 50,000 128,000 2,601,930 Jan 08 04:50 PM Maggioncalda Jeffrey Nacey President & CEO Jan 04 '24 Sale 19.09 50,000 954,320 2,551,930 Jan 08 04:50 PM Goli Shravan Chief Operating Officer Jan 02 '24 Option Exercise 2.23 43,753 97,569 853,276 Jan 04 04:33 PM Goli Shravan Chief Operating Officer Jan 02 '24 Sale 19.15 43,753 837,826 809,523 Jan 04 04:33 PM Goli Shravan Chief Operating Officer Dec 22 '23 Option Exercise 2.23 17,501 39,027 827,024 Dec 27 04:54 PM Goli Shravan Chief Operating Officer Dec 22 '23 Sale 19.94 17,501 348,910 809,523 Dec 27 04:54 PM Maggioncalda Jeffrey Nacey President & CEO Dec 21 '23 Option Exercise 2.56 50,000 128,000 2,601,930 Dec 26 07:14 PM Maggioncalda Jeffrey Nacey President & CEO Dec 22 '23 Option Exercise 2.56 13,952 35,717 2,565,882 Dec 26 07:14 PM Maggioncalda Jeffrey Nacey President & CEO Dec 26 '23 Option Exercise 2.56 11,048 28,283 2,562,978 Dec 26 07:14 PM Maggioncalda Jeffrey Nacey President & CEO Dec 21 '23 Sale 19.80 50,000 989,975 2,551,930 Dec 26 07:14 PM Maggioncalda Jeffrey Nacey President & CEO Dec 22 '23 Sale 20.03 13,952 279,456 2,551,930 Dec 26 07:14 PM Maggioncalda Jeffrey Nacey President & CEO Dec 26 '23 Sale 20.01 11,048 221,025 2,551,930 Dec 26 07:14 PM Ng Andrew Y. Director Dec 19 '23 Option Exercise 1.68 50,000 84,000 7,221,379 Dec 21 05:28 PM Ng Andrew Y. Director Dec 19 '23 Sale 20.18 50,000 1,009,080 7,171,379 Dec 21 05:28 PM Ng Andrew Y. Director Dec 20 '23 Sale 20.06 38,305 768,280 7,133,074 Dec 21 05:28 PM Goli Shravan Chief Operating Officer Dec 15 '23 Option Exercise 2.55 43,753 111,769 853,276 Dec 19 05:06 PM Goli Shravan Chief Operating Officer Dec 15 '23 Sale 20.07 43,753 878,066 809,523 Dec 19 05:06 PM HAHN KENNETH R SVP, Chief Financial Officer Dec 14 '23 Option Exercise 6.06 9,091 55,091 561,806 Dec 18 05:10 PM HAHN KENNETH R SVP, Chief Financial Officer Dec 14 '23 Sale 21.11 9,091 191,951 552,715 Dec 18 05:10 PM HAHN KENNETH R SVP, Chief Financial Officer Dec 11 '23 Option Exercise 6.06 23,869 144,646 576,584 Dec 13 05:08 PM HAHN KENNETH R SVP, Chief Financial Officer Dec 11 '23 Sale 21.06 23,869 502,777 552,715 Dec 13 05:08 PM Maggioncalda Jeffrey Nacey President & CEO Dec 07 '23 Option Exercise 2.56 75,000 192,000 2,626,930 Dec 11 04:48 PM Maggioncalda Jeffrey Nacey President & CEO Dec 07 '23 Sale 20.59 75,000 1,544,505 2,551,930 Dec 11 04:48 PM HAHN KENNETH R SVP, Chief Financial Officer Dec 06 '23 Option Exercise 6.06 24,951 151,203 577,666 Dec 06 07:24 PM HAHN KENNETH R SVP, Chief Financial Officer Dec 04 '23 Option Exercise 6.06 5,000 30,300 557,715 Dec 06 07:24 PM HAHN KENNETH R SVP, Chief Financial Officer Dec 06 '23 Sale 21.06 24,951 525,588 552,715 Dec 06 07:24 PM HAHN KENNETH R SVP, Chief Financial Officer Dec 04 '23 Sale 20.32 5,000 101,579 552,715 Dec 06 07:24 PM Maggioncalda Jeffrey Nacey President & CEO Dec 04 '23 Option Exercise 2.56 155,197 397,304 2,707,127 Dec 06 05:33 PM Maggioncalda Jeffrey Nacey President & CEO Dec 04 '23 Sale 20.21 155,197 3,136,252 2,551,930 Dec 06 05:33 PM Meyers Michele M VP, Accounting, and CAO Dec 01 '23 Sale 20.07 5,400 108,386 216,014 Dec 05 05:02 PM Goli Shravan Chief Operating Officer Dec 01 '23 Option Exercise 2.23 23,725 52,907 833,248 Dec 04 05:06 PM Goli Shravan Chief Operating Officer Nov 30 '23 Option Exercise 2.23 1,200 2,676 810,723 Dec 04 05:06 PM Goli Shravan Chief Operating Officer Dec 01 '23 Sale 20.06 23,725 475,838 809,523 Dec 04 05:06 PM Goli Shravan Chief Operating Officer Nov 30 '23 Sale 20.02 1,200 24,019 809,523 Dec 04 05:06 PM Maggioncalda Jeffrey Nacey President & CEO Dec 01 '23 Option Exercise 2.56 123,422 315,960 2,675,352 Dec 01 06:14 PM Maggioncalda Jeffrey Nacey President & CEO Nov 29 '23 Option Exercise 2.56 33,682 86,226 2,585,612 Dec 01 06:14 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
